ក្រុមហ៊ុន Sorrento Therapeutics Inc (ផ្សារហ៊ុន NASDAQ: អេស។ អរ) announced that the U.S. Bankruptcy Court for the Southern District of Texas granted interim approval of Sorrento’s $75 million debtor-in-possession financing from JMB Capital Partners.
The financing will provide Sorrento with immediate liquidity to continue operating its business as usual during its chapter 11 case.
A hearing for final financing approval is currently set for March 29, 2023.
ដែលទាក់ទង: Sorrento Therapeutics Stock Nosedive បន្ទាប់ពីដាក់ឯកសារក្ស័យធន.
As of its chapter 11 filing, Sorrento had over approximately $1 billion in assets.
Scilex Holding Company, majority-owned by Sorrento, is not a debtor in Sorrento’s chapter 11 case. Scilex continues to operate as usual, focusing on growing revenues and offering non-opioid pain management products.
Latham & Watkins LLP and Jackson Walker LLP serve as legal counsel to Sorrento. M3 Partners is serving as a restructuring advisor.
សកម្មភាពតម្លៃ: SRNE shares are up 10.9% at $0.44 on the last check Wednesday.
កុំខកខានការជូនដំណឹងតាមពេលវេលាជាក់ស្តែងលើភាគហ៊ុនរបស់អ្នក – ចូលរួម ប្រូម៉ាណា ដោយឥតគិតថ្លៃ! សាកល្បងឧបករណ៍ដែលនឹងជួយអ្នកឱ្យវិនិយោគកាន់តែឆ្លាតវៃ លឿនជាងមុន និងប្រសើរជាងមុន។.
អត្ថបទនេះ អ្នកព្យាបាលដែលក្ស័យធន Sorrento ធានាការយល់ព្រមពីតុលាការសម្រាប់ការផ្តល់ហិរញ្ញប្បទាន 75 លានដុល្លារ ដើមដំបូងបានបង្ហាញខ្លួន benzinga.com
.
© ២០២០ Benzinga.com ។ Benzinga មិនផ្តល់ដំបូន្មានវិនិយោគទេ។ រក្សារសិទ្ធគ្រប់យ៉ាង។
Source: https://finance.yahoo.com/news/bankrupt-sorrento-therapeutics-secures-court-163506123.html